Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586688 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
A NA study, sponsored by Neuronetics.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
NCT02586688: Completed NA study, sponsored by Neuronetics.
NCT02586688 is a NA study that has completed, run by Neuronetics. The registered enrollment target is 112 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02586688, a NA study, has completed, sponsored by Neuronetics.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
Primary Outcome
The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.HAM-D-24 24-item Hamilton Depression Rating Scale; Lower score is better (76 to 0)
Interventions
- DEVICE Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- DEVICE Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-12 |
| Phase | NA |
What the finished NCT02586688 record still lists
NCT02586688 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Active NeuroStar® Transcranial Magnetic Stimulation (TMS) is the first listed.
NCT02586688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02586688 about?
NCT02586688 is a clinical study titled "Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents". To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
What is the current status of trial NCT02586688?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2015-10. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02586688?
The interventions under investigation include: Active NeuroStar® Transcranial Magnetic Stimulation (TMS) (DEVICE), Sham NeuroStar® Transcranial Magnetic Stimulation (TMS) (DEVICE).
Who is sponsoring clinical trial NCT02586688?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02586688's enrollment target sits among peer trials
112 813th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia